{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Brain+Tumors+and%2For+Solid+Tumors+Including", "query": { "condition": "Brain Tumors and/or Solid Tumors Including" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Brain+Tumors+and%2For+Solid+Tumors+Including&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T21:15:49.176Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00107458", "title": "Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "valproic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 26, "start_date": "2005-05", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2014-08-07", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 15, "location_summary": "Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107458" }, { "nct_id": "NCT00077454", "title": "Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 95, "start_date": "2004-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077454" }, { "nct_id": "NCT00011414", "title": "Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Wilms' Tumor", "Sarcoma", "Adenaocortical Carcinoma", "Refractory Cancer", "Coldrhood Cancer" ], "interventions": [ { "name": "Tariquidar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 29, "start_date": "2001-02-15", "completion_date": "2016-01-13", "has_results": false, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00011414" }, { "nct_id": "NCT01130623", "title": "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Neuroblastoma", "Wilms Tumor", "Osteosarcoma", "Brain Tumor" ], "interventions": [ { "name": "Pazopanib (GW786034)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 0, "start_date": "2010-05-10", "completion_date": "2011-11-18", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01130623" }, { "nct_id": "NCT02644460", "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Brain Tumor, Recurrent", "Solid Tumor, Recurrent", "Neuroblastoma, Recurrent, Refractory", "Ewing Sarcoma, Recurrent, Refractory", "Rhabdomyosarcoma, Recurrent, Refractory", "Osteosarcoma, Recurrent, Refractory", "Rhabdoid Tumor, Recurrent, Refractory" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 53, "start_date": "2016-02", "completion_date": "2023-10-10", "has_results": false, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02644460" }, { "nct_id": "NCT00840047", "title": "Methionine PET/CT Studies In Patients With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumors and/or Solid Tumors Including", "Brain Stem Glioma", "High Grade CNS Tumors", "Ependymoma", "Medulloblastoma", "Craniopharyngioma", "Low Grade CNS Tumors", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Ewing Sarcoma", "Osteosarcoma", "Rhabdomyosarcoma", "Neuroblastoma", "Other" ], "interventions": [ { "name": "Methionine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 503, "start_date": "2009-07-20", "completion_date": "2027-07-27", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840047" }, { "nct_id": "NCT02323880", "title": "Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Glioblastoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm", "WHO Grade 3 Glioma" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 59, "start_date": "2015-10-30", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323880" }, { "nct_id": "NCT00994500", "title": "Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Medulloepithelioma", "Childhood Meningioma", "Childhood Mixed Glioma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Childhood Oligodendroglioma", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 20, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 6, "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00994500" }, { "nct_id": "NCT04870944", "title": "CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Midline Glioma, H3 K27-Altered", "Metastatic Malignant Neoplasm in the Central Nervous System", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Diffuse Midline Glioma, H3 K27-Altered", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Malignant Central Nervous System Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Malignant Central Nervous System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FACT Complex-targeting Curaxin CBL0137", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 63, "start_date": "2022-01-28", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04870944" }, { "nct_id": "NCT02780804", "title": "Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Stem Neoplasm", "Pineal Region Neoplasm", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Visual Pathway Glioma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm", "Refractory Visual Pathway Glioma" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 21, "start_date": "2017-01-06", "completion_date": "2021-09-30", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-06-25T21:15:49.176Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780804" } ] }